Research - Page 4 of 719 Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Evaluating the long-term effectiveness and safety of fixed-duration combination of ibrutinib plus obinutuzumab-based immunochemotherapy for patients with chronic lymphocytic leukemia.

Evaluating the long-term effectiveness and safety of fixed-duration combination of ibrutinib plus obinutuzumab-based immunochemotherapy for patients with chronic lymphocytic leukemia.

Posted by on Aug 27, 2023 in Leukemia | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of the fixed-duration combination of ibrutinib (Imbruvica) plus obinutuzumab (Gazyva)–based immunochemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). The data showed that a fixed-duration combination of ibrutinib plus obinutuzumab-based...

Read More

How safe and effective is prophylactic cranial irradiation in patients with extensive stage small cell lung cancer?

How safe and effective is prophylactic cranial irradiation in patients with extensive stage small cell lung cancer?

Posted by on Jul 30, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of prophylactic cranial irradiation (PCI) in patients with extensive stage (ES) small cell lung cancer (SCLC). The data indicated that PCI may decrease the occurrence of brain metastases in patients with ES-SCLC and improve 1-year survival time, without improving the overall survival...

Read More

Investigating the effectiveness of compression bandage applied with different pressures on the skin and subcutaneous tissue thickness in patients with breast cancer-related lymphedema

Investigating the effectiveness of compression bandage applied with different pressures on the skin and subcutaneous tissue thickness in patients with breast cancer-related lymphedema

Posted by on Jul 30, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of compression bandages applied with different pressures on the skin and subcutaneous tissue in patients with breast cancer-related lymphedema (BCRL). The study concluded that high-pressure compression bandage was more effective in reducing skin and subcutaneous tissue thickness and inflammation in...

Read More

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Posted by on Jul 30, 2023 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (PV; Polivy) combined with dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The data showed that PV combined with dose-adjusted EPOCH-R...

Read More

Evaluating the effects of Baduanjin exercise on motor function, balance, and gait in patients with Parkinson’s disease.

Evaluating the effects of Baduanjin exercise on motor function, balance, and gait in patients with Parkinson’s disease.

Posted by on Jul 30, 2023 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effects of Baduanjin exercise on motor function, balance, and gait in patients with Parkinson’s disease (PD). The data showed that Baduanjin exercise significantly improved motor function, balance, and gait in these patients. Some background PD is a disorder in which part of the brain is progressively...

Read More

Evaluating the long-term effectiveness and safety of adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of patients with relapsed multiple myeloma.

Evaluating the long-term effectiveness and safety of adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of patients with relapsed multiple myeloma.

Posted by on Jul 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that over the long term adding isatuximab to the Kd regimen was effective with manageable side...

Read More

Evaluating the effect of varicocele repair on sperm parameters in infertile men.

Evaluating the effect of varicocele repair on sperm parameters in infertile men.

Posted by on Jul 30, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the effect of varicocele repair (VR) on sperm parameters in infertile men with clinical varicocele. The data showed that VR significantly increased the total sperm count, sperm motility (movement), morphology (shape), and concentration in these men. Some background Male infertility can be caused by a number of...

Read More

Evaluating the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation with transurethral resection of the prostate in patients with prostate cancer.

Evaluating the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation with transurethral resection of the prostate in patients with prostate cancer.

Posted by on Jul 30, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation (HIFU) with transurethral resection of the prostate (TURP) in patients with prostate cancer (PCa). The data showed that the combination treatment of whole-gland HIFU and TURP improved the urinary outcomes in these...

Read More

Evaluating the long-term effectiveness and safety of nivolumab plus ipilimumab versus nivolumab alone after surgery in patients with stage IV melanoma.

Evaluating the long-term effectiveness and safety of nivolumab plus ipilimumab versus nivolumab alone after surgery in patients with stage IV melanoma.

Posted by on Jul 30, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus nivolumab alone given after surgery in patients with stage IV melanoma. The data showed that both nivolumab plus ipilimumab and nivolumab alone after surgery were effective compared with placebo and significantly improved survival without...

Read More

Which type of aerobic training provides greater benefits to patients with type 2 diabetes?

Which type of aerobic training provides greater benefits to patients with type 2 diabetes?

Posted by on Jul 2, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study examined the impact of three types of aerobic training exercises on measurements of heart and metabolic function in patients with type 2 diabetes (T2D). The data showed that greater improvements occurred in heart and breathing function measurements with low-volume high-intensity training (HITT) compared to low-volume...

Read More

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Read More

Evaluating the effectiveness and safety of aprocitentan for lowering blood pressure in patients with uncontrolled hypertension.

Evaluating the effectiveness and safety of aprocitentan for lowering blood pressure in patients with uncontrolled hypertension.

Posted by on Jul 2, 2023 in Hypertension | 0 comments

In a nutshell This study evaluated the effectiveness and safety of aprocitentan (ACT-132577) for lowering blood pressure (BP) in patients with resistant or uncontrolled hypertension (high BP). The data showed that aprocitentan was effective in lowering the BP after 4 weeks with a sustained effect after 40 weeks compared to a placebo with...

Read More